Description
Potential Benefits — Research Is Ongoing
These are mechanistic possibilities from the individual ingredients. Human benefits and safety of this exact three-peptide blend remain unconfirmed, and tesamorelin trial outcomes concern specific HIV populations.
- Growth-hormone release: May stimulate the body’s own growth-hormone pathways.
- Downstream tissue signalling: May influence IGF-1-related signals involved in tissue maintenance.
- Abdominal-fat metabolism: May influence growth-hormone-related pathways involved in visceral-fat regulation.
- Protein and fat metabolism: May affect the hormonal signals involved in body-composition regulation.
Research sources: Ipamorelin study; Tesamorelin trial.
Research Overview
Combines compounds relating to GHRH and ghrelin-receptor pathways. Exact CJC variant requires confirmation. Clinical benefits and safety of this blend are not established.
Mechanism / Pathway
Research examines GHRH and ghrelin-receptor pathways affecting GH and downstream IGF-1 signalling. Describing multiple pathways is not proof that their effects add together or that a co-formulated blend is stable.
Published Research
- Variant-specific long-acting CJC-1295 trial
- Ipamorelin pharmacokinetic/pharmacodynamic study
- Tesamorelin trial in HIV-associated abdominal fat accumulation
Scientific Profile
- Identity: Three-component peptide blend; the exact CJC variant requires confirmation
- Labelled components: CJC 5 mg + Ipamorelin 5 mg + Tesamorelin 2 mg; 12 mg total
- Mixture chemistry: There is no single molecular formula or molecular weight for this multi-ingredient product
- Evidence boundary: Ingredient-specific research is separated from untested finished-blend claims
Research Areas
- GHRH and ghrelin-receptor pathways affecting GH and downstream IGF-1 signalling
- Ingredient identity and variant-specific interpretation
- Combination stability, interactions and evidence gaps
Product Details
- Format: Prefilled pen
- Total contents per pen: CJC 5 mg + Ipamorelin 5 mg + Tesamorelin 2 mg — 12 mg total
Important Research Information
For laboratory, analytical and research purposes only. Not intended for human or animal consumption, diagnosis, treatment or personal use. Product quantities are not dosing instructions.
Warnings, Contraindications & Safety Information
Research use only. This is an evidence-limited safety summary, not a package insert, complete prescribing information or permission for self-administration. References to licensed medicines describe those specific products; they do not establish B&A product approval, equivalence or safety.
Contraindications & Who Should Avoid Exposure
Do not expose anyone with a known ingredient allergy. Licensed tesamorelin restrictions include pregnancy, active malignancy and certain hypothalamic-pituitary disorders. These reference restrictions do not provide a complete contraindication list for the three-ingredient blend.
Warnings & Precautions
This blend includes GHRH-related compounds and a ghrelin-receptor agonist. Raised GH/IGF-1 is not automatically a benefit; glucose intolerance, fluid retention and hypersensitivity need consideration in reference-medicine research. The exact CJC variant remains important. Human safety of this combined research presentation has not been established. Combining ingredients does not establish compatible or safe use; additional or overlapping risks may occur.
Possible Adverse Reactions
Reliable frequencies and a complete human adverse-reaction profile for this exact product are unavailable. Allergy, local irritation and contamination-related harm remain possible; absence of reports does not establish absence of risk.
Drug & Supplement Interactions
Drug and supplement interactions have not been adequately characterised for this presentation. Do not assume that combining it with prescription medicines, hormones or other research compounds is safe. Give a clinician the full ingredient list if exposure has occurred.
When to Seek Urgent Help
Seek emergency care for difficulty breathing, swelling of the face or throat, collapse, severe persistent abdominal pain, or repeated vomiting with inability to keep fluids down. Stop further exposure and show the clinician the product label and ingredient list.
Handling & Storage Cautions
Follow the actual product label and batch-specific expiry information. Do not use damaged, contaminated or unexpectedly changed material. A clear appearance, refrigeration or addition of bacteriostatic water does not prove sterility, compatibility or a safe shelf life. Do not share needles, pens or opened material between people.
Safety references: Tesamorelin medicine safety context; CJC/ipamorelin safety context. Information reviewed 25 October 2026.
Reviews
There are no reviews yet.